Previous 10 | Next 10 |
BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41 st Annual Health Care Conference....
VYNE Therapeutics (VYNE) perks 5% premarket after announcing its development plans for FMX114 for the potential treatment of mild-to-moderate atopic dermatitis ((AD)).Phase 2a clinical trial evaluating FMX114 is expected to begin in Q3 with top-line results anticipated by year end. ...
Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including clinical development plans, will be discussed on VYNE’s year end 2020 earnings call at 8:30am ET ...
BRIDGEWATER, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the year ended December 31, 2020, on Thursday, March 4, 2021, before the market open...
VYNE Therapeutics (VYNE) down 5% premarket as the company's stock-split of common shares becomes effective today.On Feb. 11, the Company's Board of Directors approved a reverse stock split at a ratio of 1-for-4.Once effective, the reverse stock split will reduce the number of common...
BRIDGEWATER, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of the Company’s common stock at a ratio of 1-for-4...
VYNE Therapeutics (VYNE) has gained ~38.9% since the company announced last week that the FDA has authorized the inclusion of new information in the product label for AMZEEQ® (minocycline) topical foam, 4%.The label update refers to a low propensity of P. acnes strains to devel...
These Penny Stocks Are Climbing Faster Than The S&P This Week When it comes to finding the best penny stocks , traders will often go with the most popular choices. Searching for hot topics on Reddit and other social media outlets has become somewhat normal in 2021. But you can...
Artelo Biosciences (ARTL) +78%.Moleculin Biotech (MBRX) +49% on announcing 100% survival achieved in Osteosarcoma Lung Metastases Animal Model.DURECT (DRRX) +42% after FDA approval for Posimir.Holicity (HOLUU) +38% on plan to take rocket maker Astra public.Tiziana Life Sciences...
Gainers: [[PRTA]] +35.6%. [[CRBP]] +30.0%. [[GPRO]] +6.8%. [[VYNE]] +5.7%. [[LOTZ]] +3.6%.Losers: [[CRUS]] -7.5%. [[RMBS]] -6.3%. [[STRO]] -6.0%. [[ALTR]] -5.4%. [[NERV]] -5.1%. For further details see: PRTA, RMBS, NERV and GPRO among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...